Aarti Pharmalabs Limited
Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals
What Aarti files
- Others55
- Investor Meet29
- Updates11
- Board Meeting10
- Important10
- Dividend/Bonus9
Aarti Pharmalabs published its FY26 Sustainability Report, highlighting strong ESG initiatives including 100% human rights training & Zero Liquid Discharge. The company is actively investing in renewable energy and sustainable sourcing. A penalty of `0.026 Cr was paid for alleged GST discrepancies.
Aarti Pharmalabs approved quarterly financial results, reporting consolidated revenue of Rs. 535.80 Cr and net profit of Rs. 76.14 Cr. The Board sanctioned a Rs. 149 Cr capex for Intermediate Block capacity expansion. Leadership updates include Rashesh C. Gogri's shift to MD and Hetal Gogri Gala's transition to Executive Director.
Aarti Pharmalabs launched the 'Saksham Niveshak' campaign. It urges shareholders to update KYC and bank details with RTA/DP to claim unpaid dividends and prevent their transfer to a government fund. Act now to secure your rightful payments.
Aarti Pharmalabs corrected its dividend announcement: the payout is for FY25-26, not FY24-25 as previously stated. This clarifies the dividend's applicable financial year.
Aarti Pharmalabs inaugurated Phase 1 of its new Atali, Gujarat plant with 440 kL reactor capacity. This 80-acre site, scalable 8-10x, targets a Rs. 1000 Cr CDMO/CMO revenue goal, significantly strengthening its product portfolio and market position.